Author: Ben Rogers
Could Breastmilk Hold the Key to Gentler IBD Treatment?
New research explores how antibodies found in breastmilk could lead to gentler IBD treatments that work with the body’s natural healing mechanisms. This approach could offer hope for managing inflammation without the harsh side effects of current therapies.
New Immune Discovery Could Transform Crohn’s Treatment Forever
Researchers have identified specific molecules that turn gut immune cells into troublemakers in Crohn’s disease. This breakthrough could lead to precision treatments that target only problematic immune pathways while preserving overall immune function.
New Single-Cell Research Offers Fresh Hope for Better Crohn’s Treatments
New single-cell research is revealing which specific immune cells drive Crohn’s inflammation, potentially leading to more precise treatments with fewer side effects. This breakthrough could transform how we approach IBD therapy by targeting only problematic cells while preserving helpful immune function.
Exercise with Crohn’s: Finding Your Path to Gentle Movement
Exercise with Crohn’s doesn’t have to look like anyone else’s routine—it just has to work for you. Gentle, consistent movement can reduce stress and improve quality of life, but the key is finding activities that feel supportive rather than demanding.
$420M Partnership Brings New Hope for Better IBD Treatments
A new $420 million partnership between Genentech and OMass Therapeutics is developing innovative oral IBD treatments using groundbreaking protein research technology. This collaboration represents significant hope for better treatment options that could transform daily life for millions living with Crohn’s disease and ulcerative colitis.
New Hope: Guselkumab Brings Targeted Relief to IBD Patients
Guselkumab, a new biologic therapy targeting IL-23, is showing remarkable promise for IBD patients with over half of Crohn’s patients achieving remission at 12 weeks. This precision approach to inflammation represents a significant advancement in treatment options for those struggling with conventional therapies.
Medicare & Entyvio: Your 2025 Coverage Guide for IBD Treatment
Understanding Medicare coverage for Entyvio can feel overwhelming, but knowing your options is crucial for maintaining access to this important IBD treatment. Here’s what you need to know before 2025, including how Part B and Part D coverage work and assistance programs that can help.
New Hope on the Horizon: TREMFYA® Gets NICE Approval for IBD
NICE has officially recommended TREMFYA® as a treatment for both Crohn’s disease and ulcerative colitis, offering new hope for patients who haven’t found success with previous therapies. This breakthrough represents a meaningful step forward for the IBD community, with evidence showing effectiveness across different patient populations.
IBD Emerges from Nigeria’s Medical Shadows: A Wake-Up Call
New research reveals IBD affects nearly 5% of colonoscopy patients in Nigeria, with most having severe, extensive inflammation but limited access to advanced treatments. This emerging picture offers important perspective on global IBD challenges and healthcare disparities.
The Smoking Paradox: What UC Research Reveals About Future Hope
New Japanese research finally explains why smoking seems to protect against UC flares—by changing gut bacteria that fight inflammation. While smoking isn’t the answer, this discovery points toward safer treatments that could replicate these protective effects without the deadly risks.
